|Novo Nordisk to offer scholarships|
WTT, Novo Nordisk team up to offer scholarships to young tennis players with diabetes
NEW YORK, N.Y. (December 17, 2007) – Novo Nordisk, a world leader in diabetes care, has signed a three-year agreement with World TeamTennis to sponsor scholarships for young tennis players with diabetes.
The Novo Nordisk Donnelly Awards will annually award $15,000 in scholarships including two one-time $5,000 scholarships given to two young people, ages 14-21, who have diabetes and play tennis competitively in tournaments or on their school team. Two regional finalist awards of $2,500 each have also been added to the scholarship program. The awards are to be used for education, tennis development and/or medical care.
World TeamTennis is currently accepting applications for the 2008 Novo Nordisk Donnelly Awards. Applications must be must be received by May 1, 2008, along with two letters of recommendation and a short essay regarding the significance of diabetes in the applicant’s life. For more details on the Novo Nordisk Donnelly Awards and to download an application form, visit www.WTT.com. For more information, contact Diane Donnelly Stone at email@example.com or 212-586-3444, x. 20.
The recipients of the $5,000 scholarships will receive their awards at a World TeamTennis Pro League match in July 2008 from WTT co-founder Billie Jean King.
Established by King, through WTT Charities, in 1998 to encourage children with diabetes to lead an active life and compete in tennis, the Novo Nordisk Donnelly Awards provide scholarships to young tennis players who are living with diabetes. The awards are named after two long-time World TeamTennis executives and tennis champions, Diane Donnelly Stone and Tracey Donnelly Maltby, who are sisters. Stone was an All-American and NCAA doubles champion at Northwestern University, and Maltby earned All-Big Ten honors at the University of Iowa. Both women have lived successfully with diabetes since childhood.
“Novo Nordisk is honored to support the World TeamTennis scholarship program,” said Dr. Henrik Rasmussen, vice president of clinical development, medical & regulatory affairs for Novo Nordisk Inc. “World TeamTennis and Novo Nordisk share a driving passion for changing diabetes for those who live with the disease by showing people an active life and pursuit of one’s dreams is possible.”
Novo Nordisk is a health care company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,000 employees in 79 countries, and markets its products in 179 countries. For more information on Novo Nordisk, visit www.NovoNordisk-us.com.
- # -